Positive allosteric modulators of the α-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid (AMPA) receptor

Journal of Medicinal Chemistry

Volumn 53, Issue 20, 2010, Pages 7271-7279

  Grove, Simon J A ^a   Jamieson, Craig ^a   MacLean, John K F ^a   Morrow, John A ^a   Rankovic, Zoran ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BENZODIOXAN 6 CARBOXYLIC ACID PIPERIDIDE; 2,3 DIHYDRO 3,4 CYCLOPENTANO 1,2,4 BENZOTHIADIAZINE 1,1 DIOXIDE; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMINO ACID RECEPTOR AFFECTING AGENT; AMPA RECEPTOR; ANIRACETAM; BRAIN DERIVED NEUROTROPHIC FACTOR; CX 614; CX 717; CYCLOTHIAZIDE; FARAMPATOR; ION CHANNEL; IONOTROPIC RECEPTOR; N [2 [4 (4 CYANOPHENYL)PHENYL]PROPYL] 2 PROPANESULFONAMIDE; N [2 [4' (2 METHYLSULFONAMIDOETHYL)BIPHENYL 4 YL]PROPYL] 2 PROPANESULFONAMIDE; NITRILE; SULFONAMIDE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; INDAZOLE DERIVATIVE; LIGAND;

BINDING SITE; CALCIUM TRANSPORT; CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; EXCITOTOXICITY; HUMAN; MEMORY DISORDER; NEUROTOXICITY; NONHUMAN; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; RECEPTOR BINDING; RECEPTOR DOWN REGULATION; REVIEW; ALLOSTERISM; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; BENZAMIDES; BENZOTHIADIAZINES; BINDING SITES; EXCITATORY AMINO ACID AGENTS; HUMANS; INDAZOLES; LIGANDS; MODELS, MOLECULAR; PROTEIN CONFORMATION; RECEPTORS, AMPA; SULFONAMIDES;

EID: 77958468790     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1000419     Document Type: Review

References (78)

1. Kew, J. N. C.; Kemp, J. A. Ionotropic and metabotropic glutamate receptor structure and pharmacology Psychopharmacology 2005, 179, 4-29
2. Mayer, M. L.; Armstrong, N. Structure and function of glutamate receptor ion channels Annu. Rev. Physiol. 2004, 66, 161-181
3. Dicou, E.; Rangon, C. M.; Guimiot, F.; Spedding, M.; Gressens, P. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain Brain Res. 2003, 970, 221-225
4. Siegel, G. J.; Chauhan, N. B. Neurotrophic factors in Alzheimers and Parkinsons disease brain Brain Res. Rev. 2000, 33, 199-227
5. Morrow, J. A.; Maclean, J. K.F.; Jamieson, C. Recent advances in positive allosteric modulators of the AMPA receptor Curr. Opin. Drug Discovery Dev. 2006, 9, 571-579
6. Marenco, S.; Weinberger, D. R. Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders CNS Drugs 2006, 20, 173-185
7. ONeill, M. J.; Dix, S. AMPA receptor potentiators as cognitive enhancers IDrugs 2007, 10, 185-192
8. ONeill, M. J.; Witkin, J. M. AMPA receptor potentiators: application for depression and Parkinsons disease Curr. Drug Targets 2007, 8, 603-620
9. Ren, J.; Poon, B. Y.; Tang, Y.; Funk, G. D.; Greer, J. J. Ampakines alleviate respiratory depression in rats Am. J. Respir. Crit. Care Med. 2006, 174, 1384-1391
10. Zarate, J.; Manji, H. K. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases Exp. Neurol. 2008, 211, 7-10
11. Palmer, C. L.; Cotton, L.; Henley, J. M. The molecular pharmacology and cell biology of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors Pharmacol. Rev. 2005, 57, 253-277
12. Sobolevsky, A. I.; Rosconi, M. P.; Gouaux, E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor Nature 2009, 462, 745-756
13. Figures were generated using Protein Data Bank entry 3KG2.
14. Sun, Y.; Olson, R.; Horning, M.; Armstrong, N.; Mayer, M.; Gouaux, E. Mechanism of glutamate receptor desensitization Nature 2002, 417, 245-253
15. Jin, R.; Singh, S. K.; Gu, S.; Furukawa, H.; Sobolevsky, A. I.; Zhou, J.; Jin, Y.; Gouaux, E. Crystal structure and association behaviour of the GluR2 amino-terminal domain EMBO J. 2009, 28, 1812-1823
16. Clayton, A.; Siebold, C.; Gilbert, R. J. C.; Sutton, G. C.; Harlos, K.; McIlhinney, R. A. J.; Jones, E. Y.; Aricescu, A. R. Crystal structure of the GluR2 amino-terminal domain provides insights into the architecture and assembly of ionotropic glutamate receptors J. Mol. Biol. 2009, 392, 1125-1132
17. Jin, R.; Clark, S.; Weeks, A. M.; Dudman, J. T.; Gouaux, E.; Partin, K. M. Mechanism of positive allosteric modulators acting on AMPA receptors J. Neurosci. 2005, 25, 9027-9036
18. Armstrong, N.; Sun, Y.; Chen, G. Q.; Gouaux, E. Structure of a glutamate-receptor ligand-binding core in complex with kainate Nature 1998, 395, 913-917
19. Kaae, B. H.; Harpsøe, K.; Kastrup, J. S.; Sanz, A. C.; Pickering, D. S.; Metzler, B.; Clausen, R. P.; Gajhede, M.; Sauerberg, P.; Liljefors, T.; Madsen, U. Structural proof of a dimeric positive modulator bridging two identical AMPA receptor-binding sites Chem. Biol. 2007, 14, 1294-1303
20. Frandsen, A.; Pickering, D. S.; Vestergaard, B.; Kasper, C.; Nielsen, B. B.; Greenwood, J. R.; Campiani, G.; Fattorusso, C.; Gajhede, M.; Schousboe, A.; Kastrup, J. S. Tyr702 is an important determinant of agonist binding and domain closure of the ligand-binding core of GluR2 Mol. Pharmacol. 2005, 67, 703-713
21. Jin, R.; Banke, T. G.; Mayer, M. L.; Traynelis, S. F.; Gouaux, E. Structural basis for partial agonist action at ionotropic glutamate receptors Nat. Neurosci. 2003, 6, 803-810
22. Ptak, C. P.; Ahmed, A. H.; Oswald, R. E. Probing the allosteric modulator binding site of GluR2 with thiazide derivatives Biochemistry 2009, 48, 8594-8602
23. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific: Palo Alto, CA, 2002.
24. Johansen, T. H.; Chaudhary, A.; Verdoorn, T. A. Interactions among GYKI-52466, cyclothiazide and aniracetam at recombinant AMPA and kainate receptors Mol. Pharmacol. 1995, 48, 946-955
25. Copani, A.; Genazzani, A. A.; Aleppo, G.; Casabona, G.; Canonico, P. L.; Scapagnini, U.; Nicoletti, F. Nootropic drugs positively modulate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-sensitive glutamate receptors in neuronal cultures J. Neurochem. 1992, 58, 1199-1204
26. Arai, A. C.; Xia, Y.-F.; Rogers, G.; Lynch, G.; Kessler, M. Benzamide-type AMPA receptor modulators form two subfamilies with distinct modes of action J. Pharmacol. Exp. Ther. 2002, 303, 1075-1085
27. Lynch, G. S.; Rogers, G. A. Drugs That Enhance Synaptic Responses Mediated by AMPA Receptors. WO/1994/02475, 1994.
28. Ornstein, P. L.; Zimmerman, D. M.; Arnold, M. B.; Bleisch, T. J.; Cantrel, B.; Simon, R.; Zarrinmayeh, H.; Baker, S. R.; Gates, M.; Tizzano, J. P.; Bleakman, D. Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxzol-4-yl)-propanoic acid (AMPA) receptors J. Med. Chem. 2000, 43, 4354-4354
29. Wezenberg, E.; Verkes, R. J.; Ruigt, G. S. F.; Hulstijn, W.; Sabbe, B. G. C. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers Neuropsychopharmacology 2007, 32, 1272-1283
30. Rogers, G. A.; Nilssen, L. Benzoyl Piperidines/Pyrrolidines for Enhancing Synaptic Response. WO/1996/38414, 1996.
31. Arai, A. C.; Kessler, M.; Rogers, G.; Lynch, G. Effects of the potent ampakine CX614 on hippocampal and recombinant AMPA receptors: interactions with cyclothiazide and GYKI 52466 Mol. Pharmacol. 2000, 58, 802-803
32. Rogers, G. A.; Lynch, G. S. Benzoxazines for Enhancing Synaptic Response. WO/1997/36907, 1997.
33. Rogers, G. A.; Marrs, C. Benzoxazine Compounds for Enhancing Synaptic Response. WO/1999/33469, 1999.
34. Rogers, G. A.; Johnstrom, P. Acylbenzoxazines for Enhancing Synaptic Response. WO/1999/51240, 1999.
35. Rogers, G. A.; Marrs, C. M. Benzofurazan Compounds Which Enhance AMPA Receptor Activity. WO/1998/35950, 1998.
36. Grove, S. J. A.; Zhang, M.; Shahid, M. Benzoxazapine Derivatives and Their Use as AMPA Receptor Stimulators. WO/2002/100865, 2002.
37. Grove, S. J. A.; Adam-Worrall, J.; Zhang, M.; Gilfillan, R. Pyrido/Thieno-[ f ]-oxazipine-5-one Derivatives as Positive Modulators of the AMPA Receptor. WO/2002/102808, 2002.
38. Cordi, A.; Rogers, G.; Mueller, R. 3-Substituted-[1,2,3]-Benzotriazinone Compounds for Enhancing Glutamategic Synaptic Response. WO/2008/085506, 2008.
39. Lynch, G.; Granger, R.; Ambros-Ingerson, J.; Davis, C. M.; Kessler, M.; Schehr, R. Evidence That a Positive Modulator of AMPA-Type Glutamate Receptors Improves Delayed Recall in Aged Humans Exp. Neurol. 1997, 145, 89-92
40. Lynch, G.; Kessler, M.; Rogers, G.; Ambros-Ingerson, J.; Granger, R.; Schehr, R. S. Psychological effects of a drug that facilitates brain AMPA receptors Int. Clin. Psychopharmacol. 1996, 11, 13-19
41. Marenco, S.; Weinberger, D. R. Therapeutic potential of positive AMPA receptor modulators in the treatment of neuropsychiatric disorders CNS Drugs 2006, 20, 173-185
42. Goff, D. C.; Lamberti, J. S.; Leon, A. C.; Green, M. F.; Miller, A. L.; Patel, J.; Manschreck, T.; Freudenreich, O.; Johnson, S. A. A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia Neuropsychopharmacology 2008, 33, 465-472
43. Wesensten, N. J.; Reichardt, R. M.; Balkin, T. J. Ampakine (CX717) effects on performance and alertness during simulated night shift work Aviat., Space Environ. Med. 2007, 78, 937-943
44. Oertel, B. G.; Felden, L.; Tran, P. V; Bradshaw, M. H.; Angst, M. S.; Schmidt, H.; Johnson, S.; Greer, J. J.; Geisslinger, G.; Varney, M. A.; Lötsch, J. Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia Clin. Pharmacol. Ther. 2010, 87, 204-211
45. Pirotte, B.; Podona, T.; Diouf, O.; de Tullio, P.; Lebrun, P.; Dupont, L.; Somers, F.; Delarge, J.; Morain, P.; Lestage, P.; Lepagnol, J.; Spedding, M. 4 H -1,2,4-Pyridothiadiazine 1,1-dioxides and 2,3-dihydro-4 H -1,2,4-pyridothiadiazine 1,1-dioxides chemically related to diazoxide and cyclothiazide as powerful positive allosteric modulators of (R / S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid receptors: design, synthesis, pharmacology, and structure-activity relationships J. Med. Chem. 1998, 41, 2946-2959
46. Desos, P.; Cordi, A.; Lestage, P. Derivatives of Benzothiazine and Benzothiadiazine, Process for Their Preparation, and Pharmaceutical Compositions Containing Them as AMPA Receptor Modulators. EP/1486503, 2004.
47. Bourasset, F.; Bernard, K.; Munoz, C.; Genissel, P.; Scherrmann, J. M. Neuropharmacokinetics of a new {alpha}-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) modulator, S18986 [(S)-2,3-dihydro-[3,4]cyclopentano-1,2, 4-benzothiadiazine-1,1-dioxide] in the rat Drug Metab. Dispos. 2005, 33, 1137-1143
48. Lestage, P.; Danober, L.; Lockhart, B.; Roger, A.; Lebrun, C.; Robin, J.-L.; Desos, P.; Cordi, A. 48 S-18986, positive allosteric modulator of AMPA receptors as a novel cognition enhancer in rodents Res. Pract. Alzheimers Dis. 2002, 6, 253-259
49. Arnold, M. B.; Jones, W. D.; Ornstein, P. L.; Zarrinmayeh, H.; Zimmerman, D. M. Preparation of N-Substituted Sulfonamide Derivatives for Potentiating Glutamate Receptor Function. WO/2000/006537, 2000.
50. Quirk, J. C.; Nisenbaum, E. S. LY404187: a novel positive allosteric modulator of AMPA receptors CNS Drug Rev. 2002, 8, 255-282
51. Miu, P.; Jarvie, K. R.; Radhakrishnan, V.; Gates, M. R.; Ogden, A.; Ornstein, P. L.; Zarrinmayeh, H.; Ho, K.; Peters, D.; Grabell, J.; Gupta, A.; Zimmerman, D. M.; Bleakman, D. Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro Neuropharmacology 2001, 40, 976-983 (Pubitemid 32530603)
52. Baumbarger, P. J.; Muhlhauser, M.; Zhai, J.; Yang, C. R.; Nisenbaum, E. S. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator J. Pharmacol. Exp. Ther. 2001, 298, 86-102
53. Arundine, M.; Tymianski, M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury Cell. Mol. Life Sci. 2004, 61, 657-668
54. Vandergriff, J.; Huff, K.; Bond, A.; Lodge, D. Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo Neuropharmacology 2001, 40, 1003-1009
55. Arnold, M. B.; Bleisch, T. J.; Cuff, G. W.; Ornstein, P. L.; Zimmerman, D. M. Preparation of [[[(Methylsulfonamido)ethyl]phenyl]phenyl]propyl Sulfonamide Derivatives with Glutamate Receptor Function Potentiating Activity. WO/2001/090057, 2001.
56. Miller, W. D.; Fray, A. H.; Quatroche, J. T.; Sturgill, C. D. Suppression of a Palladium-Mediated Homocoupling in a Suzuki Cross-Coupling Reaction. Development of an Impurity Control Strategy Supporting Synthesis of LY451395 Org. Process Res. Dev. 2007, 11, 359-364
57. Jhee, S. S.; Chappell, A. S.; Zarotsky, V.; Moran, S. V.; Rosenthal, M.; Kim, E.; Chalon, S.; Toublanc, N.; Brandt, J.; Coutant, D. E.; Ereshefsky, L. Multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects J. Clin. Pharmacol. 2006, 46, 424-432
58. Chappell, A. S.; Gonzales, C.; Williams, J.; Witte, M. M.; Mohs, R. C.; Sperling, R.; Chappell, A. S.; Gonzales, C.; Williams, J.; Witte, M. M.; Mohs, R. C.; Sperling, R. AMPA potentiator treatment of cognitive deficits in Alzheimer disease Neurology 2007, 68, 1008-1012
59. Knobelsdorf, J. A.; Zarrinmayeh, H. Preparation and Formulation of (Bis)sulfonamides for Pharmaceutical Use Potentiating Glutamate Receptor Function and Treating a Wide Variety of Conditions, Such as Psychiatric and Neurological Disorders. WO/2001/094306, 2001.
60. Merck internal data.
61. 3H] N -2-(4-(N -Benzamido)phenyl)propyl-2-propanesulfonamide: a novel AMPA receptor potentiator and radioligand J. Med. Chem. 2001, 44, 302-304 (Pubitemid 32113580)
62. Shepherd, T. A.; Aikins, J. A.; Bleakman, D.; Cantrell, B. E.; Rearick, J. P.; Simon, R. L.; Smith, E. C.; Stephenson, G. A.; Zimmerman, D. M.; Mandelzys, A.; Jarvie, K. R.; Ho, K.; Deverill, M.; Kamboj, R. K. Design and synthesis of a novel series of 1,2-disubstituted cyclopentanes as small, potent potentiators of 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propanoic acid (AMPA) receptors J. Med. Chem. 2002, 45, 2101-2111
63. Bradley, D. M.; Thewlis, K. M.; Ward, S. E. Preparation of N -Indan-2-yl and Related Sulfonamides That Potentiate Glutamate Receptor for Use against Schizophrenia. WO/2006/015828, 2006.
64. Andreotti, D.; Ward, S. E. Preparation of N -[2-Phenyltetrahydrofuran-3- yl]-2-propanesulfonamide Derivatives as Glutamate Receptor Modulators. WO/2007/090841, 2007.
65. Thewlis, K. M.; Ward, S. E. Preparation of 4-Phenyl-3- (isopropylsulfonylamino)tetrahydrofuran Derivatives as Glutamate Receptor Modulators for Treatment of Schizophrenia. WO/2007/090840, 2007.
66. Ward, S. E.; Thewlis, K. M. Preparation of N -Indan-2-yl and Related Sulfonamides That Potentiate Glutamate Receptor for Use against Schizophrenia. WO/2006/015829, 2007.
67. Thewlis, K. M.; Ward, S. E. Preparation of N -Pyrrolidinyl Sulfonamides That Potentiate Glutamate Receptor for Use against Schizophrenia. WO/2006/015827, 2006.
68. Ward, S. E.; Harries, M.; Aldegheri, L.; Andreotti, D.; Ballantine, S.; Bax, B. D.; Harries, A. J.; Harker, A. J.; Lund, J.; Melarange, R.; Mingardi, A.; Mookherjee, C.; Mosley, J.; Neve, M.; Oliosi, B.; Profeta, R.; Smith, K. J.; Smith, P. W.; Spada, S.; Thewlis, K. M.; Yusaf, S. P. Discovery of N -[(2S)-5-(6-Fluoro-3pyridinyl)-2,3-dihydro-1 H -indenyl]-2-propane sulfonamide, a Novel Clinical AMPA Receptor Positive Modulator J. Med. Chem. 2010, 53, 5801-5812
69. Estep, K. G.; Fliri, A. F. J.; ODonnell, C. J. Sulfonamides and Pharmaceutical Compositions Thereof. WO/2008/120093, 2008.
70. Bradley, D. M.; Chan, W. N.; Harrison, S.; Thatcher, R.; Thewlis, K. M.; Ward, S. E. Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine. WO/2007/107539, 2007.
71. Bradley, D. M.; Chan, W. N.; Thewlis, K. M.; Ward, S. E. Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine. WO/2008/053031, 2008.
72. Bradley, D. M.; Chan, W. N.; Ward, S. E. Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine.WO/2008/148836, 2008
73. Bertheleme, N.; Bradley, D. M.; Cardullo, F.; Merlo, G.; Pozzan, A.; Scott, J. S.; Thewlis, K. M.; Ward, S. E. Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine. WO/2008/113795, 2008.
74. Bertheleme, N.; Bradley, D. M.; Cardullo, F.; Merlo, G.; Pozzan, A.; Scott, J. S.; Thewlis, K. M.; Ward, S. E. Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine. WO/2008/003452, 2008.
75. Zarrinmayeh, H,; Tromiczak, E.; Zimmerman, D. M.; Rankl, N.; Ho, K. H.; Dominguez, E.; Castano, A.; Escribano, A.; Fernandez, C.; Jimenez, A.; Hornback, W. J.; Nisenbaum, E. S. A novel class of positive allosteric modulators of AMPA receptors: design, synthesis, and structure-activity relationships of 3-biphenyl-4-yl-4-cyano-5-ethyl-1-methyl-1 H -pyrrole-2-carboxylic acid, LY2059346 Bioorg. Med. Chem. Lett. 2006, 16, 5203-5206
76. Konkoy, C. S.; Fick, D. B.; Cai, S. X.; Lan, N. C.; Keana, J. F. W. Substituted 5-Oxo-5,6,7,8-tetrahydro-4 H -1-benzopyrans and Benzothiopyrans and Their Use as Potentiators of AMPA. WO/2000/075123, 2000.
77. Winter, K.; Weiser, T.; Blech, S. M.; Ceci, A. Preparation of Azaacenaphthylene Dioxides and Related Compounds as Positive Allosteric AMPA Receptor Modulators (PAARM). WO/2001/057045, 2001.
78. Bradley, D. M.; Chan, W. N.; Harrison, S.; Hughes, O.; Miller, D. D.; Neesom, J.; Thewlis, K. M.; Ward, S. E. Compounds Which Potentiate AMPA Receptor and Uses Thereof in Medicine. WO/2007/122241, 2007.